CN111298097B - Application of cortistatin14 in preparation of drugs for treating autoimmune inflammatory diseases - Google Patents
Application of cortistatin14 in preparation of drugs for treating autoimmune inflammatory diseases Download PDFInfo
- Publication number
- CN111298097B CN111298097B CN202010234020.0A CN202010234020A CN111298097B CN 111298097 B CN111298097 B CN 111298097B CN 202010234020 A CN202010234020 A CN 202010234020A CN 111298097 B CN111298097 B CN 111298097B
- Authority
- CN
- China
- Prior art keywords
- inflammatory diseases
- psoriasis
- tnf
- application
- minutes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DDRPLNQJNRBRNY-WYYADCIBSA-N cortistatin-14 Chemical compound C([C@H]1C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N1)NC(=O)[C@H]1NCCC1)C(=O)N[C@@H](CCCCN)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 DDRPLNQJNRBRNY-WYYADCIBSA-N 0.000 title claims abstract description 50
- 101800002195 Cortistatin-14 Proteins 0.000 title claims abstract description 47
- 239000003814 drug Substances 0.000 title claims abstract description 37
- 229940079593 drug Drugs 0.000 title claims description 17
- 208000037979 autoimmune inflammatory disease Diseases 0.000 title abstract description 10
- 238000002360 preparation method Methods 0.000 title description 8
- 239000000499 gel Substances 0.000 claims description 9
- 239000006071 cream Substances 0.000 claims description 8
- 239000002674 ointment Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 19
- 201000004681 Psoriasis Diseases 0.000 abstract description 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 11
- 239000005557 antagonist Substances 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 10
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical group OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 8
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 abstract description 6
- 238000010171 animal model Methods 0.000 abstract description 6
- 102000003298 tumor necrosis factor receptor Human genes 0.000 abstract description 6
- 230000007774 longterm Effects 0.000 abstract description 5
- 206010025135 lupus erythematosus Diseases 0.000 abstract description 5
- 102000003390 tumor necrosis factor Human genes 0.000 abstract description 4
- 208000027866 inflammatory disease Diseases 0.000 abstract description 3
- 201000008482 osteoarthritis Diseases 0.000 abstract description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract description 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 abstract description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 abstract description 2
- 230000009878 intermolecular interaction Effects 0.000 abstract description 2
- 230000001681 protective effect Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 208000011594 Autoinflammatory disease Diseases 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 102000006240 membrane receptors Human genes 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 49
- 238000012546 transfer Methods 0.000 description 17
- 239000012528 membrane Substances 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 201000004624 Dermatitis Diseases 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 9
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 9
- 239000008096 xylene Substances 0.000 description 9
- 102100040247 Tumor necrosis factor Human genes 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 210000002540 macrophage Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 229960002751 imiquimod Drugs 0.000 description 6
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 6
- 239000012188 paraffin wax Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 229920001220 nitrocellulos Polymers 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 4
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 102400001054 Cortistatin-17 Human genes 0.000 description 3
- 101800002188 Cortistatin-17 Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010008165 Etanercept Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102100025136 Macrosialin Human genes 0.000 description 2
- 101100425758 Mus musculus Tnfrsf1b gene Proteins 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 2
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229960000403 etanercept Drugs 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 102100030851 Cortistatin Human genes 0.000 description 1
- 229930185483 Cortistatin Natural products 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- -1 and thus Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 108010005430 cortistatin Proteins 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses an application of a tumor necrosis factor antagonist cortistatin14 in preparing a medicament for treating autoimmune inflammatory diseases. Cortistatin14 can directly bind to tumor necrosis factor TNF-alpha cell surface receptor, antagonize TNF-alpha function, and play a protective role in autoimmune inflammatory diseases such as psoriasis. The results of intermolecular interaction experiments show that cortistatin14 can bind directly to the cell surface receptor TNFR, a key molecule of TNF- α in a variety of auto-inflammatory diseases including psoriasis. Meanwhile, animal models show that the cortistatin14 can inhibit the occurrence of various inflammatory diseases such as psoriasis and the like and improve the state of an illness, has no obvious toxic or side effect after long-term application, can be used in the fields of psoriasis, lupus erythematosus, rheumatoid arthritis, osteoarthritis and the like, and has wide application value and market prospect.
Description
Technical Field
The invention relates to the field of medicine, in particular to application of cortistatin14 in preparation of a medicament for treating autoimmune inflammatory diseases.
Background
At present, autoimmune inflammatory diseases such as psoriasis and the like are common in clinic, patients generally need long-term drug therapy, wherein TNF-alpha antagonist drugs are the most common drugs with definite therapeutic effect at present [1], and the drugs are widely applied in the world. The clinically used TNF-alpha antagonist drug comes from bioengineering pharmacy, the related drugs have few types, the patient selection margin is small, the synthesis cost of the related drugs is high, and the economic burden is caused to the patient needing long-term application. Meanwhile, currently used TNF- α antagonist drugs have their own potential side effects and the possibility of increasing risks such as infection to various degrees, and the TNF- α cell surface antibody TNFR, which is one of the main binding sites, is also intensively studied and explored, for example, etanercept, which is currently used clinically, directly binds TNFR to inhibit the progression of inflammatory diseases [2 ]. Most of the currently used medicines are biological agents [3], the cost is high, potential risks such as infection exist, and the use is influenced to a certain extent.
1.Dervieux,T.,Kremer,J.M.&Weinblatt,M.E.(2019)Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept,Annals of the rheumatic diseases.78,1285-1286.
2.Murray,K.M.&Dahl,S.L.(1997)Recombinant human tumor necrosis factor receptor(p75)Fc fusion protein(TNFR:Fc)in rheumatoid arthritis,The Annals of pharmacotherapy.31,1335-8.
3.Moulis,G.,Pugnet,G.,Costedoat-Chalumeau,N.,Mathian,A.,Leroux,G.,Boutemy,J.,Espitia,O.,Bouillet,L.,Berthier,S.,Gaultier,J.B.,Jeandel,P.Y.,Konate,A.,Mekinian,A.,Solau-Gervais,E.,Terrier,B.,Wendling,D.,Andry,F.,Garnier,C.,Cathebras,P.,Arnaud,L.,Palmaro,A.,Cacoub,P.,Amoura,Z.,Piette,J.C.,Arlet,P.,Lapeyre-Mestre,M.&Sailler,L.(2018)Efficacy and safety of biologics in relapsing polychondritis:a French national multicentre study,Annals of the rheumatic diseases.77,1172-1178.
Disclosure of Invention
The invention aims to provide an application of a tumor necrosis factor antagonist cortistatin14 in preparing autoimmune inflammatory disease treatment medicines, wherein the cortistatin14 serving as a TNF-alpha antagonist medicine has the effects of relieving inflammatory reaction and improving the conditions of inflammatory diseases such as psoriasis and the like, in-vitro experiments show that the cortistatin14 has no risk of increasing tumors and the like, and the medicine is safe for long-term use.
The technical scheme of the invention is as follows:
cortistatin14 (Cortistatin14, abbreviated as CST-14), CAS: 186901-48-4. Its molecular weight is 21 kD.
The amino acid sequence of CST-14 is:
Pro-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Ser-Ser-Cys-Lys
(Disulfide bridge: Cys2-Cys13), which is also an advantage over other TNF antagonists. Meanwhile, the synthesis purity of the compound can reach over 99.5 percent at present, and the purity meets the requirement of medicine preparation.
The invention provides an application of a tumor necrosis factor antagonist cortistatin14 in preparing autoimmune inflammatory disease treatment medicines, in particular to the application of the cortistatin14 as a tumor necrosis factor antagonist to antagonize TNF-alpha function.
In particular to the application in preparing the psoriasis treatment medicine.
Also includes the application in preparing the medicine for treating rheumatoid arthritis and osteoarthritis.
And predictable use in the treatment of lupus erythematosus.
The medicine also comprises a pharmaceutically acceptable carrier, an auxiliary agent or a diluent.
The form of the medicament is selected from one of the following forms: sprays, aerosols, solutions, lotions, gels, ointments, pastes, emulsions and suspensions.
Preferably, the form of the medicament is selected from one of the following: cream and ointment.
For an ointment, the ointment comprises an agent selected from the group consisting of: stearic acid, stearyl alcohol, cetyl alcohol, glycerol, water, and mixtures thereof, and the medicament has a physiologically acceptable pH.
For a cream, the cream comprises an agent selected from the group consisting of: stearic acid, stearyl alcohol, cetyl alcohol, glycerol, water, and mixtures thereof, and the medicament has a physiologically acceptable pH.
The medicament is preferably in an injection form, and the administration mode is preferably nanoparticle-mediated local administration.
In addition, cortistatin-17 belongs to another existing form of cortistatin in animals and humans, and studies show that cortistatin-14 and cortistatin-17 have similarities in function, so that cortistatin-17 has the possibility of developing and applying in autoimmune diseases in the future.
The results of intermolecular interaction experiments through in vitro binding experiments and in vivo animal model experiments show that cortistatin14 (CST-14) can directly bind to a tumor necrosis factor TNF-alpha cell surface receptor, antagonize TNF-alpha function, and play a protective role in autoimmune inflammatory diseases such as psoriasis. CST-14 belongs to a novel TNF-alpha antagonist and can be directly synthesized by the prior art, thereby reducing the cost. In addition, in the animal model, the long-term application of CST-14 has no obvious toxic or side effect, and can be used in the fields of psoriasis, lupus erythematosus, rheumatoid arthritis, osteoarthritis and the like.
Drawings
FIG. 1 is a graph of the visual therapeutic effect of cortistatin14 in mouse dermatitis
FIG. 2 is a psoriasis score for the effect of cortistatin14 on treatment of mouse dermatitis
FIG. 3 is the CO-IP measured ability of cortistatin14 to bind to TNF
FIG. 4 is a solid phase binding assay for determining the binding ability of cortistatin14 to the tumor necrosis factor receptors TNFR1 and TNFR2
FIG. 5 is a graph of the effect of cortistatin14 on macrophage polarization process in animal models
Figure 6 is a histological study examining the effect of cortistatin14 in reducing epidermal proliferation and inflammatory cell infiltration in a mouse model of dermatitis.
FIG. 7 is a visual comparison of MRL/lpr knockout mouse models in systemic lupus erythematosus animal experiments
FIG. 8 comparison of spleen volumes in MRL/lpr knockout mouse model for systemic lupus erythematosus animal experiments
FIG. 9 comparison of body weights of MRL/lpr knockout mice model in systemic lupus erythematosus animal experiments
FIG. 10 osteosarcoma HOS cell scratch test
FIG. 11 statistical analysis of osteosarcoma HOS cell scratch experiment
FIG. 12EdU experiment
Detailed Description
Sources of experimental animals, reagents, media and buffers referred to in the following examples:
cortisan 14 (purity 98.4%, CAS:186901-48-4, amino acid sequence Pro-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Ser-Ser-Cys-Lys (Disulfide bridge: Cys2-Cys13)) (Gill Biochemical Co., Ltd.)
BL6/C57 male mouse (Shandong university animal center)
PBS buffer (Biyuntian biological reagent company)
F4/80 antibody, CD86 antibody, CD206 antibody (Thermo Fisher, Pierce)
RIPA cell protein extraction lysate (Thermo Fisher, Pierce)
Protease inhibitor (Beijing Solaibao Tech Co., Ltd.)
BCA protein quantification kit (Shanghai Yanxi Biotech Co., Ltd.)
Complete EDTA-Free (Roche biomedicine)
Xylene (national drug group chemical reagent Co., Ltd.)
Neutral gum (Shanghai Tantake skill Co., Ltd.)
Concentrated hydrochloric acid (national drug group chemical reagent Co., Ltd.)
Eosin (Shanghai Tantake skill Co., Ltd.)
Hematoxylin (Shanghai Tantake skill Co., Ltd.)
Methanol (national medicine group chemical reagent Co., Ltd.)
Citrate buffer (0.01M, pH 6.0) (Biotechnology engineering, Shanghai Co., Ltd.)
10% NGS (biological engineering Shanghai share Co., Ltd.)
Hydrogen peroxide (H2O2) (national drug group chemical Co., Ltd.)
BSA (Biotechnology Shanghai GmbH)
Absolute alcohol (national medicine group chemical reagent Co., Ltd.)
Cell counter was purchased from Thermo Fisher, USA
Microscope from Shanghai Caikang optical instruments Ltd
Centrifuge from Jinan Olaibo medical instruments Ltd
Electronic balance from medical instruments ltd, denna olabo
Enzyme-linked immunosorbent assay (ELISA) instrument purchased from Beijing Meihua apparatus science and technology Limited
Flow cytometry was purchased from BD Co
Ice machine from Jinan Ou Laibo medical instruments Ltd
Ultra pure water system is commercially available from Jinan Oolabo medical instruments Ltd
Vortex mixer from Jinan Olaibo medical devices, Inc
Biocare 3000 available from GE health care
1. Construction of mouse model for skin inflammation
A mouse model of imiquimod (imiquimod) induced skin inflammation was established in 10 week old wild type BL6/C57 male mice (total of 42). First, all mice were shaved of their dorsal skin with a razor and depilatory cream. Wild type mice (14) from the blank group were daily coated with petrolatum cream on shaved back skin and injected intraperitoneally with sterile PBS buffer. Wild type mice (14) of the experimental treatment group were then coated daily with 62.5mg of 5% imiquimod cream on shaved back skin and injected intraperitoneally with exogenous cortistatin14 (1 μ g/200 μ l) for 1 week. Wild type mice (14) in the scytotis group were daily coated with 62.5mg of 5% imiquimod cream on shaved back skin and injected intraperitoneally with equal amounts of sterile PBS buffer. The assessment of differentiating the severity of skin inflammation was made based on the psoriasis-like skin area severity index using clinical scores as previously reported. In short, erythema, scaling and thickening were scored 0 to 4 (0: none; 1: mild; 2: moderate; 3: significant; 4: severe). Cumulative scores (ratio: 0-12) of these three parameters are shown to assess the severity of skin inflammation. Two experimenters do not influence each other by adopting a double-blind method and independently score. After 1 week, all groups of mice were euthanized with an excess of 10% chloral hydrate (qiu hospital, shandong university, china) and dorsal skin specimens were collected for subsequent testing.
Fig. 1 and 2 are graphs of the results of this experiment, showing that psoriasis dermatitis in mice has significant relief from treatment with cortistatin14 by visual photographs and psoriasis scores.
2. Flow cytometry analysis of macrophages
To determine macrophage subpopulations, mouse skin samples from an imiquimod-induced mouse model of skin inflammation were ground to a single cell suspension, filtered through a 200 mesh screen and stained for flow cytometry. Briefly, fluorescently conjugated antibodies (anti-F4/80, anti-CD 86, anti-CD 206) were added to a single cell suspension (100. mu.l). After gentle mixing, the samples were incubated at 4 ℃ for 20 minutes and then analyzed using a flow cytometer. Macrophage subpopulation analysis was determined by analyzing the percentage of positive cells and the intensity of the positive signal. Flow cytometer parameter setting: FITC is detected through an FITC channel (FL-1), the excitation wavelength is 488nm, and the emission wavelength is 530 nm; PI is detected through FL-2 channel, excitation wavelength 488nm, emission wavelength 630 nm.
Fig. 5 shows that, by flow cytometry, cortistatin14 has a good therapeutic effect in dermatitis by regulating macrophage polarization to M2 subtype with anti-inflammatory function.
3. Tissue slice preparation
The skin of mice from all groups was fixed in 10% formalin for at least 72 hours at room temperature. Sequentially dehydrating the tissue with 50% ethanol (60 min), 70% ethanol (60 min), 85% ethanol (60 min), 95% ethanol (60 min), 100% ethanol (30 min), and 100% ethanol (30 min); sequentially treating the mixture with ethanol, xylene (60 minutes) and xylene (60 minutes); then clear with xylene and paraffin (60 min), paraffin (80 min); the tissue was placed in a cassette, filled with paraffin, and then placed on the cold plate of a paraffin embedding machine. Placing the embedded tissue paraffin block on a microtome and sectioning the tissue to a thickness of about 4 μm; the organized paraffin pieces were lightly smeared in water at 42 ℃. After completely flattening, lightly pulling up the slices by using a clean glass sheet; the sections were placed on glass slides, numbered, and baked in an oven at 68 ℃ for at least 6 hours.
4. Hematoxylin/eosin staining
The slices were dewaxed with a conventional fat-soluble solvent to water (xylene twice, 15 min/each time; 100% alcohol 5 min; 95% alcohol 5 min; 75% alcohol 5 min; 50% alcohol 5 min), then stained with hematoxylin staining solution for 5min, rinsed with clear water, then stained with eosin staining solution for 5min, rinsed with clear water, dehydrated (50% alcohol 5 min; 75% alcohol 5 min; 95% alcohol 5 min; 100% alcohol 5 min; xylene twice, 15 min/each time), after which the slices were air-dried, they were sealed with neutral gum, and observed and analyzed under an optical microscope.
5. Immunohistochemical staining
Tissue sections were deparaffinized and hydrated. I.e., 8 minutes of xylene, 8 minutes of absolute ethanol, 8 minutes of 95% ethanol, 8 minutes of 80% ethanol, and 8 minutes of 75% ethanol in succession. After 8 minutes in 70% ethanol, the sections were rinsed 4 times for 5 minutes each; next, the deparaffinized and hydrated sections were placed in a 3% hydrogen peroxide solution and reacted at 37 ℃ for 20 minutes to block endogenous peroxidase. Antigen was restored by washing 4 times with double distilled water each time, 5 minutes each time. The citrate buffer was placed in a metal heater and boiled. Boil for 15 minutes, turn off power and hold for 15 minutes. Naturally cooling to room temperature; PBS was then washed 5 times each for 5 minutes, the surrounding tissue was wiped, 5% goat serum was added, non-specific antigen was blocked, reaction was performed at room temperature for 1 hour, then CD68 antibody was added drop-wise to the tissue slices and incubated overnight in a wet box at 4 ℃; the next day, sections were removed, incubated in an incubator at 37 ℃ for 1 hour, rinsed 5 times with PBS every 15 minutes, and an enhanced horseradish peroxidase-conjugated secondary antibody was added and incubated at room temperature for 2 hours. Excess secondary antibody was washed with PBS (5 times for 5 minutes each); dropwise adding a freshly prepared DAB coloring solution, observing under an optical microscope, and taking on a brown yellow color, and washing with PBS to stop color development; next, hematoxylin counterstaining was performed. The stained sections were placed in modified hematoxylin stain and stained for 5 minutes. The staining was observed under an optical microscope. The sections were then separated with 0.2% hydrochloric acid and washed with running water. Finally, the slices were sequentially rinsed with 70% alcohol for 10 minutes, 75% alcohol for 8 minutes, 80% alcohol for 8 minutes, 90% alcohol for 8 minutes, absolute ethanol for 8 minutes, xylene for 8 minutes, and xylene for 8 minutes. After dehydrating for 2 minutes, the tissue surrounding the tissue was wiped and a neutral gel was dropped, and the cover glass was placed under an optical microscope for observation.
Fig. 6 is a graph showing the results of the above experiments 4 and 5, and a graph showing HE staining results showing that cortistatin14 treatment has an excellent alleviating effect on the infiltration of inflammatory cells such as macrophages into the skin.
Panel B is an immunohistochemical staining using CD68 immunohistochemistry as a marker molecule for macrophages, confirming the function of cortistatin-14 to improve inflammatory cell infiltration in the psoriasis model.
CO-IP and Western blot detection
180. mu.l of RIPA lysate was removed, and 200ul of tissue lysate was prepared by adding 10ul of protease inhibitor and 10ul of phosphatase inhibitor. Then placing the frozen chondrocyte sample taken out from a refrigerator at the temperature of-80 ℃ in an EP tube, adding the prepared tissue lysate, and placing the EP tube in a homogenizer pre-cooled by liquid nitrogen for homogenization; the homogenization time and number are set. After complete homogenization of the cells, the EP tubes were removed, centrifuged at 12000rpm, centrifuged at 15 ℃ for 15 minutes, and the supernatant was transferred to a new 1.5ml EP tube. About 20ul of cell lysis supernatant was left and boiled with 2Xloading buffer for 5min to obtain input group. Agarose beads (S beads) were aliquoted into new EP tubes in advance, using tips cut off to aspirate beads, and ensuring consistent amounts of beads in each tube, carefully aspirating the supernatant, adding protein A antibodies and cell lysed supernatant. 1mg of protein lysate was added to 25ul of suspension containing 1: 1S beads and 2ug of protein A antibody. Shaking table incubation at 4 deg.C for 2-4h, Binding, 1400rx1min, and centrifuging at 4 deg.C. Sucking the supernatant by a vacuum pump or a pipette, paying attention to no suction of the precipitate, adding 800ul of NETN, inverting and mixing up and down to ensure that the precipitate at the bottom is suspended, centrifuging, washing beads for three times, discarding the supernatant for the last time, sucking up residual liquid by a spotting gun head, adding 15ul of 2xloading buffer for boiling for 5min to be used as Co-IP group spotting, and adding 10ul of 2xloading buffer to the residual precipitate for boiling once again to be used as IP group spotting.
The electrophoresis tank is placed on an electrophoresis device, and the power supply is turned on, and the positive electrode and the negative electrode are installed. The voltage was adjusted to about 150V to maintain a constant voltage. When the bromophenol blue label moved to the bottom of the gel, the power was turned off and the running buffer was poured back into the vial. Preparing 1000mL of membrane transfer buffer solution and precooling at 4 ℃; soaking 2 pieces of thick filter paper (about 8 × 10cm in size) and nitrocellulose membrane 30 min before electrophoresis, and soaking sponge clips in the transfer buffer; immersing the glass plate in the transfer solution, carefully taking out the glass plate with a plastic spatula, taking the gel off the glass, and removing all the concentrated gel and unnecessary separating gel; assembling a film transfer interlayer according to the sequence of sponge-filter paper-gel-nitrocellulose film-filter paper-sponge; placing the transfer clip into a transfer tank to ensure that the gel side of the transfer clip faces the cathode and the side of the membrane faces the anode, adding an appropriate amount of buffer solution to the transfer tank to ensure that the transfer clip is completely immersed in water, and placing the transfer clip into an ice box; inserting the black electrode lead into a cathode socket of the film transfer device, inserting the red electrode lead into an anode socket, and connecting the anode lead and the cathode lead to corresponding power supply outputs; placing the film rotating device on ice, turning on a power supply, setting the transfer condition of the instrument to be constant current 240mA, and setting the film transfer time to be 90 min; after the transfer, the film was taken out from the transfer apparatus and transferred to a cassette, the press plate was carefully opened to transfer the PVDF film layer by tweezers, the nitrocellulose PVDF film was taken out, and a corner was cut at the upper right near the film as a mark. Blocking and antibody incubation: the transferred nitrocellulose membrane was taken out, washed with TBST for 1 minute, and the transfer solution remaining on the membrane was washed off and then placed face up in a 5% nonfat dry milk blocking solution. The membrane was cut to size and ready for primary antibody incubation at room temperature on a shaker for 1 hour. Primary antibody incubation: diluting the primary antibody, soaking the membrane in a proper amount of diluted primary antibody, and putting the membrane into a refrigerator at 4 ℃ overnight (8-12 h). Washing a primary antibody: the membrane was removed and washed with TBST on a shaker for 5min 3 times. And (3) secondary antibody incubation: the concentration of the goat anti-rabbit secondary antibody and the goat anti-mouse secondary antibody is 1: 10000 secondary antibody dilution. The membrane was immersed in an appropriate amount of diluted secondary antibody and incubated at room temperature for 1 hour. Washing a secondary antibody: after removal of the membrane, it was washed 5min × 3 times with TBST on a shaker. And (3) developing: the same amount of the hypersensitive ECL chemiluminescent kit was taken and mixed well with liquid a and liquid B, shielded from light, and then the nitrocellulose membrane was placed on a black film, right side up, and an appropriate amount of the chromogenic mixture was applied to the film with a pipette at room temperature for development and imaging in a gel imaging system.
FIG. 3 shows that, in chondrocytes, cortistatin-14 can form a complex with cell surface tumor necrosis factor receptors TNFR1 and TNFR2, and thus, cortistatin-14 binds to TNFR1 and TNFR 2.
Fig. 3 and 4 are graphs showing the results of direct binding of cortistatin14 to tumor necrosis factor receptors TNFR1 and TNFR 2. FIG. 3 shows that cortistatin14 is bound to TNF receptor by antibody detection as measured by CO-IP, and FIG. 4 shows that A-B is measured by solid phase binding assay, and that cortistatin14 has direct binding ability to TNF receptor.
Through the experiments, the CST-14 can be directly combined with the cell surface receptor TNFR of the TNF-alpha, has exact curative effect on an imiquimod induced psoriasis animal model, and effectively promotes the macrophage to be converted into an M2 anti-inflammatory subtype. Meanwhile, cortistatin-14 is a polypeptide molecule with a molecular weight of 21kD, which is significantly smaller than that of earlier-stage similar preparations (etanercept, infliximab, adalimumab, etc.), and the single dosage can be reduced in comparison.
7. Animal experiments
Animal experiments show that the molecule is used for a long time (the mouse experiment lasts for more than 3 months) and no obvious organ damage and mouse behavior change are observed.
In addition, mouse experiments were also performed for lupus erythematosus, another common autoimmune inflammatory disease. FIG. 7, 8 and 9 show that the CST treatment has a relieving effect on lupus occurrence of mice, and the body weight of the mice has no obvious change after the cortistatin-14 treatment for 3 months, as shown by an animal experiment MRL/lpr gene knockout mouse model of systemic lupus erythematosus.
In FIG. 7, it is shown that SLE facial plaque alopecia and skin lesions are significantly reduced, in FIG. 8 splenomegaly is shown in the non-treated group and cortistatin-14 is shown in the treated group. Figure 9 shows no significant difference in body weight between the two groups.
Meanwhile, the early in vitro cell data show that cortistatin-14 stimulates tumor cells to produce no obvious sign of migration and proliferation. In FIG. 10, osteosarcoma HOS cell scratch assay; FIG. 11, statistical analysis of scratches, cortistatin-14 did not significantly promote migration; figure 12EdU experiment, cortistatin-14 stimulation did not significantly stimulate HOS cell proliferation compared to control.
Both tests are commonly known in the art and are not described herein.
All data are expressed as mean standard deviations of at least three independent experiments. Statistical analysis for two groups of data statistical analysis using paired t-tests more than two groups of data statistical analysis using one-way analysis of variance.
More importantly, the CST-14 is simple to prepare, the preparation method is pure and mature, the preparation method can be directly synthesized, and the early-stage similar drugs are all biological agents, so that the cost of the CST-14 can be obviously reduced compared with other similar TNF-alpha inhibitors, and the economic burden of patients is reduced.
While one embodiment of the present invention has been described in detail, the description is only a preferred embodiment of the present invention and should not be taken as limiting the scope of the invention. All equivalent changes and modifications made within the scope of the present invention shall fall within the scope of the present invention.
Claims (5)
1. Application of cortistatin14 in preparing systemic lupus erythematosus treatment drugs.
2. The use of claim 1, wherein the medicament further comprises a pharmaceutically acceptable carrier, adjuvant or diluent.
3. The use of claim 1, wherein the medicament is in a form selected from one of: sprays, aerosols, solutions, lotions, gels, ointments, creams, salves, pastes, emulsions, suspensions.
4. The use of claim 1, wherein the medicament is in an injectable dosage form.
5. The use of claim 1, wherein the medicament is administered topically using nanoparticle-mediated delivery.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010234020.0A CN111298097B (en) | 2020-03-30 | 2020-03-30 | Application of cortistatin14 in preparation of drugs for treating autoimmune inflammatory diseases |
| CN202210364438.2A CN115120702A (en) | 2020-03-30 | 2020-03-30 | Application of cortistatin14 in preparation of psoriasis treatment medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010234020.0A CN111298097B (en) | 2020-03-30 | 2020-03-30 | Application of cortistatin14 in preparation of drugs for treating autoimmune inflammatory diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210364438.2A Division CN115120702A (en) | 2020-03-30 | 2020-03-30 | Application of cortistatin14 in preparation of psoriasis treatment medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111298097A CN111298097A (en) | 2020-06-19 |
| CN111298097B true CN111298097B (en) | 2022-05-06 |
Family
ID=71155948
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210364438.2A Pending CN115120702A (en) | 2020-03-30 | 2020-03-30 | Application of cortistatin14 in preparation of psoriasis treatment medicine |
| CN202010234020.0A Active CN111298097B (en) | 2020-03-30 | 2020-03-30 | Application of cortistatin14 in preparation of drugs for treating autoimmune inflammatory diseases |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210364438.2A Pending CN115120702A (en) | 2020-03-30 | 2020-03-30 | Application of cortistatin14 in preparation of psoriasis treatment medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN115120702A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113797314B (en) * | 2021-09-29 | 2023-08-22 | 山东大学齐鲁医院 | Application of CST polypeptide in preparing medicine for treating femoral head necrosis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10174587A (en) * | 1996-06-07 | 1998-06-30 | Takeda Chem Ind Ltd | New peptide, its production and use |
| CN104673735A (en) * | 2015-03-05 | 2015-06-03 | 华中农业大学 | CST (cortistatin) and SS (somatostatin) double-expression DNA vaccine as well as preparation method and application thereof |
-
2020
- 2020-03-30 CN CN202210364438.2A patent/CN115120702A/en active Pending
- 2020-03-30 CN CN202010234020.0A patent/CN111298097B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10174587A (en) * | 1996-06-07 | 1998-06-30 | Takeda Chem Ind Ltd | New peptide, its production and use |
| CN104673735A (en) * | 2015-03-05 | 2015-06-03 | 华中农业大学 | CST (cortistatin) and SS (somatostatin) double-expression DNA vaccine as well as preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| Cortistatin Dampens Psoriasis-Like Skin Inflammation Through Interacting with TNF-Α/TNFR1/Nf-κB Signaling Pathway and Regulating Macrophage Polarization;Wenhan Wang等;《SSRN》;20191219;摘要 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111298097A (en) | 2020-06-19 |
| CN115120702A (en) | 2022-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Henke et al. | MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions | |
| Fabricant et al. | Increased serum levels of nerve growth factor in von Recklinghausen's disease | |
| Kim et al. | Increased expression of cathelicidin by direct activation of protease-activated receptor 2: possible implications on the pathogenesis of rosacea | |
| WO2008141438A1 (en) | Gabaergic modulators for treating airway conditions | |
| Xia et al. | iTRAQ-based quantitative proteomic analysis of the inhibition of cervical cancer cell invasion and migration by metformin | |
| Eiró et al. | Duodenal expression of Toll-like receptors and interleukins are increased in both children and adult celiac patients | |
| Gonçalves et al. | p27 kip1 overexpression regulates VEGF expression, cell proliferation and apoptosis in cell culture from eutopic endometrium of women with endometriosis | |
| Sultan et al. | Evaluation of the antifungal and wound-healing properties of a novel peptide-based bioadhesive hydrogel formulation | |
| Yang et al. | Astragalus extract attenuates allergic airway inflammation and inhibits nuclear factor κB expression in asthmatic mice | |
| DE60219809T2 (en) | Compounds and methods for the detection of carcinomas and their precursors | |
| CN111298097B (en) | Application of cortistatin14 in preparation of drugs for treating autoimmune inflammatory diseases | |
| CN111388651B (en) | Application of CST-14 in preparation of osteoporosis treatment medicine | |
| JP2019189651A (en) | Identification of new polypeptide hormone for maintenance of optimal body weight and blood glucose | |
| Morales et al. | Functional consequences of interactions between FAK and epithelial membrane protein 2 (EMP2) | |
| CN114668846A (en) | Application of deubiquitinase USP45 in preparation of medicine for treating esophageal cancer | |
| Graff et al. | Extracellular matrix remodeling in atopic dermatitis harnesses the onset of an asthmatic phenotype and is a potential contributor to the atopic march | |
| WO2024026384A1 (en) | Assays for detection and quantitation of human endotrophin | |
| Jagadeeshaprasad et al. | 4-Aminopyridine Induces Nerve Growth Factor to Improve Skin Wound Healing and Tissue Regeneration | |
| CN116953237A (en) | Human auxiliary transcription factor 4 ubiquitination site for tumor diagnosis and treatment and application thereof | |
| Majewski et al. | Olive leaf‐derived PPAR agonist complex induces collagen IV synthesis in human skin models | |
| US11175289B2 (en) | Application of TRPM8 protein, related peptide fragment and their antibodies | |
| CN113855675A (en) | Kit and medicine based on gallbladder cancer marker | |
| Kim et al. | Exogenous CLASP2 protein treatment enhances wound healing in vitro and in vivo | |
| KR101754478B1 (en) | Biomarker composition for diagnosing atrophic vaginitis and kit for the same | |
| WO2018198054A1 (en) | Kit for the assessment of endometrial receptivity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240418 Address after: No. 77 Wenhua West Road, Lixia District, Jinan City, Shandong Province, 250000, Jin Guang Wang Jiao 2-1304 Patentee after: Jinan Tongyao Medical Equipment Co.,Ltd. Country or region after: China Address before: 250000 No. 107 Cultural West Road, Jinan City, Shandong Province Patentee before: QILU HOSPITAL OF SHANDONG University Country or region before: China |
|
| TR01 | Transfer of patent right |